reportingrisk.com← the monitorSEC reporting failures, scored and checked against what happened next

Or browse all companies A–Z.

Ernexa Therapeutics Inc.

ERNA · Nasdaq

No reporting failures in the last 12 months

It filed on time and stood behind its numbers. Of companies scoring zero, 4.0% were delisted, went bankrupt, restated or stopped filing within the following year.

$18Mpublic float
2025-07-07most recent failure

Score over time

0246202220232024202520262022-01-01 · score 22021-09-23 auditor change2021-04-23 auditor change2022-04-01 · score 32022-01-24 auditor change2021-09-23 auditor change2021-04-23 auditor change2022-07-01 · score 62022-06-17 accounts unreliable2022-05-17 filed late (10-Q) · acquisition or merger2022-04-19 auditor change2022-04-01 filed late (10-K) · auditor2022-01-24 auditor change+1 more2022-10-01 · score 52022-06-17 accounts unreliable2022-05-17 filed late (10-Q) · acquisition or merger2022-04-19 auditor change2022-04-01 filed late (10-K) · auditor2022-01-24 auditor change2023-01-01 · score 52022-06-17 accounts unreliable2022-05-17 filed late (10-Q) · acquisition or merger2022-04-19 auditor change2022-04-01 filed late (10-K) · auditor2022-01-24 auditor change2023-04-01 · score 42022-06-17 accounts unreliable2022-05-17 filed late (10-Q) · acquisition or merger2022-04-19 auditor change2022-04-01 filed late (10-K) · auditor2025-10-01 · score 12025-07-07 auditor change2026-01-01 · score 12025-07-07 auditor change2026-04-01 · score 12025-07-07 auditor change2026-07-01 · score 12025-07-07 auditor change

Hover or tap a dot to see the filings behind that score.

Why they said they were late

Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”, “ we ”, “ us ” or “ our ”), is filing this Notification of Late Filing on Form 12b-25 with respect to its Quarterly Report on Form 10-Q for the three months ended March 31, 2022 (the “ Form 10-Q ”). The Company could not file the Form 10-Q within the prescribed time period required for smaller reporting companies without unreasonable effort and expense because additional time is required by the Company’s management to complete its preparation of the financial statements and accompanying disclosures for the period ended March 31, 2022. In particular, the Company is reviewing certain valuation methodologies used to value both the IRX-2 assets acquired by the Company and the related contingent consideration obligations assumed by the Company in its 2018 acquisition of IRX Therapeutics, Inc. and any internal control implications. The Company is diligently working towards filing the Form 10-Q no later than the fifth calendar day following the prescribed due date

NT 10-Q, filed 2022-05-17 · acquisition or merger

What it filed

2025-07-07auditor changed or resigned SEC →

2022-06-17accounts declared unreliable SEC →

2022-05-17filed late (10-Q)acquisition or merger SEC →

Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”, “ we ”, “ us ” or “ our ”), is filing this Notification of Late Filing on Form 12b-25 with respect to its Quarterly Report on Form 10-Q for the three months ended March 31, 2022 (the “ Form 10-Q ”). The Company could not file the Form 10-Q within the prescribed time period required for smaller reporting companies without unreasonable effort and expense because additional time is required by the Company’s management to complete its preparation of the financial statements and accompanying disclosures for the period ended March 31, 2022. In particular, the Company is reviewing certain valuation methodologies used to value both the IRX-2 assets acquired by the Company and the related contingent consideration obligations assumed by the Company in its 2018 acquisition of IRX Therapeutics, Inc. and any internal control implications. The Company is diligently working towards filing the Form 10-Q no later than the fifth calendar day following the prescribed due date

2022-04-19auditor changed or resigned SEC →

2022-04-01filed late (10-K)auditor SEC →

Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”, “ we ”, “ us ” or “ our ”), is filing this Notification of Late Filing on Form 12b-25 with respect to its Annual Report on Form 10-K for the year ended December 31, 2021 (the “ Form 10-K ”). The Company could not file the Form 10-K within the prescribed time period required for smaller reporting companies without unreasonable effort and expense because additional time is required by the Company’s management, working in conjunction with the Company’s independent auditors, to complete the Company’s audit for the year ended December 31, 2021. The Company is diligently working with its auditors and anticipates that it will file the Form 10-K no later than the fifteenth calendar day following the prescribed due date

2022-01-24auditor changed or resigned SEC →

2021-09-23auditor changed or resigned SEC →

2021-04-23auditor changed or resigned SEC →

About this score

reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.

Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.

See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.

Every item above is a filing this company made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not investment advice

reportingrisk.com← back to the monitorAll companies A-Z · RSS · found an error? hello@reportingrisk.com